PRQR Earnings Date: Nov 5, 2026 (Estimated) — ProQR Therapeutics N.V.
NASDAQ · Healthcare · Biotechnology
Updated
When is PRQR's next earnings date?
ProQR Therapeutics N.V. (PRQR) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.11 on revenue of $4.3M.
How did PRQR do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), ProQR Therapeutics N.V. posted EPS of -$0.09 versus the -$0.13 estimate, a beat of 35.7%. Revenue was $10.2M against a $4.6M estimate. The stock's 1-day post-earnings move was -0.5%.
How much does PRQR stock move after earnings?
PRQR beat EPS estimates in 3 of its last 7 reported quarters. Over the last 8 reports the stock moved an average of 5.7% (up or down) in the day after earnings.
About ProQR Therapeutics N.V.
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.13 | -0.09 | +35.71% | $10.2M | ✅ Beat | -0.54% | +19.35% | +0.00% |
| 2026-05-12 | Q1 2026 | -0.15 | -0.15 | +0.00% | $2.4M | ➖ Inline | -0.62% | -6.21% | -12.42% |
| 2026-03-12 | Q4 2025 | -0.08 | -0.09 | -12.50% | $5.5M | ❌ Miss | -4.97% | -4.97% | +2.21% |
| 2025-11-06 | Q3 2025 | -0.10 | -0.10 | +0.00% | $2.9M | ➖ Inline | -7.14% | -9.24% | -12.18% |
| 2025-03-13 | Q4 2024 | -0.15 | -0.10 | +33.33% | $4.6M | ✅ Beat | -5.95% | -11.89% | -38.92% |
| 2024-11-07 | Q3 2024 | -0.11 | -0.11 | +0.00% | $4.2M | ➖ Inline | -1.92% | +8.79% | -2.20% |
| 2024-03-13 | Q4 2023 | — | -0.08 | — | $3.5M | — | +13.66% | +22.44% | +12.20% |
| 2023-11-07 | Q3 2023 | -0.09 | -0.08 | +11.11% | $1.5M | ✅ Beat | +10.66% | +14.75% | +63.93% |
Showing last 8 quarters.